Trial · NCT01974245
Supplementation With Cholecalciferol in Dialysis Patients
NCT01974245, Phase 2, Completed, Federal University of São Paulo; results first posted 2014-12-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Supplementation With Cholecalciferol in Dialysis Patients. Trials, record NCT01974245. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01974245
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Supplementation With Cholecalciferol in Dialysis Patients
- NCT number
- NCT01974245
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- Federal University of São Paulo
- Conditions
- Chronic Kidney Disease
- Interventions
- Cholecalciferol, Placebo
- First posted
- 2013-11-01
- Last updated
- 2025-03-14
- Results first posted
- 2014-12-12
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Interleukin-6 at 12 Weeks. | 12 weeks | |
| Secondary | Change From Baseline in C-reactive Protein at 12 Weeks | 12 weeks | |
| Other | Change From Baseline in Expression in Monocytes of Vitamin D Receptor, α 1-hydroxylase and 24-hydroxylase Enzymes, and Interleukin-6 at 12 Weeks | 12 weeks |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Interleukin-6 at 12 Weeks. | 12 weeks | pg/mL | MEAN | |
| SECONDARY | Change From Baseline in C-reactive Protein at 12 Weeks | 12 weeks | |||
| OTHER_PRE_SPECIFIED | Change From Baseline in Expression in Monocytes of Vitamin D Receptor, α 1-hydroxylase and 24-hydroxylase Enzymes, and Interleukin-6 at 12 Weeks | 12 weeks |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Interleukin-6 at 12 Weeks. | Placebo | Interleukin-6 baseline | 9.0 | Standard Deviation 5.2 | pg/mL |
| Change From Baseline in Interleukin-6 at 12 Weeks. | Cholecalciferol | Interleukin-6 baseline | 8.1 | Standard Deviation 6.6 | pg/mL |
| Change From Baseline in Interleukin-6 at 12 Weeks. | Placebo | Interleukin-6 after intervention | 9.6 | Standard Deviation 5.6 | pg/mL |
| Change From Baseline in Interleukin-6 at 12 Weeks. | Cholecalciferol | Interleukin-6 after intervention | 4.6 | Standard Deviation 4.1 | pg/mL |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 27 | |
| Overall Study | STARTED | Cholecalciferol | 28 | |
| Overall Study | COMPLETED | Placebo | 18 | |
| Overall Study | COMPLETED | Cholecalciferol | 20 | |
| Overall Study | NOT COMPLETED | Placebo | 9 | |
| Overall Study | NOT COMPLETED | Cholecalciferol | 8 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Cholecalciferol | ||
| Total, other adverse events | Placebo | 0 | 18 |
| Total, other adverse events | Cholecalciferol | 0 | 20 |
| Total, serious adverse events | Placebo | 0 | 18 |
| Total, serious adverse events | Cholecalciferol | 0 | 20 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27161894 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Cholecalciferol vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01974245
GET https://conductscience.org/api/trials/v1/NCT01974245/registered